SmitW., SchoutenN., van den BergN., LangedijkM.J., StruijkD.G., KredietR.T.Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a cross-sectional study.Perit Dial Int2004; 24(6): 562–70.
2.
MateijsenM.A., van der WalA.C., HendriksP.M., ZweersM.M., MulderJ., StruijkD.G.Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis.Perit Dial Int1999; 19(6): 517–25.
3.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R.Morphologic changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13(2): 470–9.
4.
HondaK., NittaK., HoritaS., YumuraW., NiheiH.Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure.Nephron1996; 72(2): 171–6.
5.
Di PaoloN., SacchiG.Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy.Perit Dial Int1989; 9(1): 41–5.
6.
BreborowiczA., RodelaH., OreopoulosD.G.Toxicity of osmotic solutes on human mesothelial cells in vitro.Kidney Int1992; 41(5): 1280–5.
7.
GotloibL., WaisbrutV., ShostakA., KushnierR.Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions.Nephron1995; 70(4): 466–77.
8.
NakayamaM., KawaguchiY., YamadaK., HasegawaT., TakazoeK., KatohN.Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD.Kidney Int1997; 51(1): 182–6.
9.
ZweersM.M., SplintL.J., KredietR.T., StruijkD.G.Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat.Nephrol Dial Transplant2001; 16(3): 651–4.
10.
ZweersM.M., de WaartD.R., SmitW., StruijkD.G., KredietR.T.Growth factors VEGF and TGF-beta1 in peritoneal dialysis.J Lab Clin Med1999; 134(2): 124–32.
11.
ZweersM.M., StruijkD.G., SmitW., KredietR.T.Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up.J Lab Clin Med2001; 137(2): 125–32.
12.
DaviesS.J., PhillipsL., NaishP.F., RussellG.I.Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis.J Am Soc Nephrol2001; 12(5): 1046–51.
13.
HendriksP.M., Ho-dac-PannekeetM.M., van GulikT.M., StruijkD.G., PhoaS.S., SieL.Peritoneal sclerosis in chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors, and peritoneal transport kinetics.Perit Dial Int1997; 17(2): 136–43.
14.
WieslanderA.P., AndrenA.H., Nilsson-ThorellC., MuscaluN., KjellstrandP.T., RippeB.Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro?Perit Dial Int1995; 15(8): 348–52.
15.
HaH., YuM.R., LeeH.B.High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells.Kidney Int2001; 59(2): 463–70.
16.
LeungJ.C., ChanL.Y., LiF.F., TangS.C., ChanK.W., ChanT.M.Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF.Nephrol Dial Transplant2005; 20(7): 1336–49.
17.
KredietR.T., ZweersM.M., van WhesthrenenR., ZegwaardA., StruijkD.G.Effects of reducing the lactate and glucose content of PD solutions on the peritoneum. Is the future GLAD?NDT Plus2008; 1(Suppl 4): iv56–62.
18.
Ho-dac-PannekeetM.M., SchoutenN., LangendijkM.J., HiralallJ.K., de WaartD.R., StruijkD.G.Peritoneal transport characteristics with glucose polymer based dialysate.Kidney Int1996; 50(3): 979–86.
19.
MistryC.D., GokalR., PeersE.A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis.Kidney Int1994; 46(2): 496–503.
20.
LinA., QianJ., LiX., YuX., LiuW., SunY.Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid.Clin J Am Soc Nephrol2009; 4(11): 1799–804.
21.
DaviesS.J., WoodrowG., DonovanK., PlumJ., WilliamsP., JohanssonA.C.Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial.J Am Soc Nephrol2003; 14(9): 2338–44.
22.
JonesM., HagenT., BoyleC.A., VoneshE., HamburgerR., CharytanC.Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study.Am J Kidney Dis1998; 32(5): 761–9.
SeoE.Y., AnS.H., ChoJ.H., SuhH.S., ParkS.H., GwakH.Effect of bio-compatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials.Perit Dial Int2014; 34(7): 724–31.
26.
Rodriguez-CarmonaA., Perez FontanM., Garcia LopezE., Garcia FalconT., Diaz CambreH.Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study.Perit Dial Int2007; 27(3): 260–6.
27.
GobinJ., FernandoS., SantacroceS., FinkelsteinF.O.The utility of two daytime icodextrin exchanges to reduce dextrose exposure in automated peritoneal dialysis patients: a pilot study of nine patients.Blood Purif2008; 26(3): 279–83.
28.
HolmesC.J., ShockleyT.R.Strategies to reduce glucose exposure in peritoneal dialysis patients.Perit Dial Int2000; 20(Suppl 2): S37–41.
29.
le PooleC.Y., van IttersumF.J., WeijmerM.C., ValentijnR.M., ter WeeP.M.Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study.Adv Perit Dial2004; 20: 170–6.
30.
le PooleC.Y., WeltenA.G., ter WeeP.M., PaauwN.J., DjoraiA.N., ValentijnR.M.A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation.Perit Dial Int2012; 32(3): 305–15.
31.
LiP.K., CulletonB.F., ArizaA., DoJ.Y., JohnsonD.W., SanabriaM.Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients.J Am Soc Nephrol2013; 24(11): 1889–900.
32.
YungS., LuiS.L., NgC.K.F., YimA., MaM.K.M., LoK.Y.Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.Perit Dial Int2015; 35(2): 147–58.
33.
LuiS.L., YungS., YimA., WongK.M., TongK.L., WongK.S.A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.Am J Kidney Dis2012; 60(6): 966–75.
34.
Lopes BarretoD., KredietR.T.Current status and practical use of effluent biomarkers in peritoneal dialysis patients.Am J Kidney Dis2013; 62(4): 823–33.
